Go to deals
Food & Beverage | Private Equity

Luigi Lavazza SpA has acquired Onda Coffee Break

Lavazza, one of the largest espresso coffee producers in the world, has acquired Onda Coffee Break, the leading coffee shop chain in Bulgaria, for an undisclosed consideration.

The acquisition, completed in pursuit of Lavazza’s international growth strategy, represents an important investment aimed at consolidating the group's presence in Bulgaria, where espresso coffee consumption is growing rapidly. As a result of this transaction, Lavazza has acquired eleven shops located in key shopping areas in Sofia. Lavazza will gradually increase the visibility of its own brand within the Onda chain, aiming at turning its coffee shops into a showcase for authentic Italian espresso coffee in Eastern Europe.

Onda Coffee Break was formerly controlled by Global Finance, the largest private equity fund in the region, together with smaller local shareholders.

Oaklins' team in Italy originated the deal and assisted Lavazza throughout the acquisition process.

Parties

Talk to the deal team

Giuseppe Maria Bernardo Puccio

Principal
Milan, Italy
Oaklins Italy

Related deals

ELSA Group has sold SoFine Foods to The New Originals Company
Food & Beverage

ELSA Group has sold SoFine Foods to The New Originals Company

The New Originals Company has acquired SoFine Foods from the ELSA Group.

Learn more
Den Berk Délice accelerates growth through strategic partnership
Private Equity | Agriculture

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more